

Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma

Annette M. Molinaro, PhD; Shawn Hervey-Jumper, MD, PhD; Ramin A. Morshed, MD; Jacob Young, MD; Seunggu J. Han, MD; Pranathi Chunduru, MS; Yalan Zhang, MS; Joanna J. Phillips, MD, PhD; Anny Shai, PhD; Marisa Lafontaine, MS; Jason Crane, PhD; Ankush Chandra, BS; Patrick Flanigan, MD; Arman Jahangiri, MD, PhD; Gino Cioffi, MPH; Quinn Ostrom, PhD; John E. Anderson, MD; Chaitra Badve, MD; Jill Barnholtz-Sloan, PhD; Andrew E. Sloan, MD; Bradley J. Erickson, MD, PhD; Paul A. Decker, MS; Matthew L. Kosel, BS; Daniel LaChance, MD; Jeanette Eckel-Passow, PhD; Robert Jenkins, MD, PhD; Javier Villanueva-Meyer, MD; Terri Rice, MPH; Margaret Wrensch, PhD; John K. Wiencke, PhD; Nancy Ann Oberheim Bush, MD, PhD; Jennie Taylor, MD; Nicholas Butowski, MD; Michael Prados, MD; Jennifer Clarke, MD; Susan Chang, MD; Edward Chang, MD; Manish Aghi, MD, PhD; Philip Theodosopoulos, MD; Michael McDermott, MD; Mitchel S. Berger, MD

IMPORTANCE Per the World Health Organization 2016 integrative classification, newly diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (*IDH*)-wild-type and *IDH*-mutant subtypes, with median patient survival of 1.2 and 3.6 years, respectively. Although maximal resection of contrast-enhanced (CE) tumor is associated with longer survival, the prognostic importance of maximal resection within molecular subgroups and the potential importance of resection of non-contrast-enhanced (NCE) disease is poorly understood.

OBJECTIVE To assess the association of resection of CE and NCE tumors in conjunction with molecular and clinical information to develop a new road map for cytoreductive surgery.

DESIGN, SETTING, AND PARTICIPANTS This retrospective, multicenter cohort study included a development cohort from the University of California, San Francisco (761 patients diagnosed from January 1, 1997, through December 31, 2017, with 9.6 years of follow-up) and validation cohorts from the Mayo Clinic (107 patients diagnosed from January 1, 2004, through December 31, 2014, with 5.7 years of follow-up) and the Cleveland Clinic's Ohio Brain Tumor Study (99 patients with data collected from January 1, 2008, through December 31, 2011, with a median follow-up of 10.9 months). Image assessors were blinded to patient groupings. Eligible patients underwent surgical resection for newly diagnosed glioblastoma and had available survival, molecular, and clinical data and preoperative and postoperative magnetic resonance images. Data were analyzed from November 15, 2018, to March 15, 2019.

MAIN OUTCOMES AND MEASURES Overall survival.

RESULTS Among the 761 patients included in the development cohort (468 [61.5%] men; median age, 60 [interquartile range, 51.6-67.7] years), younger patients with *IDH*-wild-type tumors and aggressive resection of CE and NCE tumors had survival similar to that of patients with *IDH*-mutant tumors (median overall survival [OS], 37.3 [95% CI, 31.6-70.7] months). Younger patients with *IDH*-wild-type tumors and reduction of CE tumor but residual NCE tumors fared worse (median OS, 16.5 [95% CI, 14.7-18.3] months). Older patients with *IDH*-wild-type tumors benefited from reduction of CE tumor (median OS, 12.4 [95% CI, 11.4-14.0] months). The results were validated in the 2 external cohorts. The association between aggressive CE and NCE in patients with *IDH*-wild-type tumors was not attenuated by the methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase.

CONCLUSIONS AND RELEVANCE This study confirms an association between maximal resection of CE tumor and OS in patients with glioblastoma across all subgroups. In addition, maximal resection of NCE tumor was associated with longer OS in younger patients, regardless of *IDH* status, and among patients with *IDH*-wild-type glioblastoma regardless of the methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase. These conclusions may help reassess surgical strategies for individual patients with newly diagnosed glioblastoma.

JAMA Oncol. doi:10.1001/jamaoncol.2019.6143
Published online February 6, 2020.

[+ Invited Commentary](#)

[+ Supplemental content](#)

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Annette Molinaro, PhD, Neurological Surgery, University of California, San Francisco, 1450 3rd St, San Francisco, CA 94143 (annette.molinaro@ucsf.edu).

In 2016, the World Health Organization (WHO) reclassified glioma by integrating molecular and histologic characteristics. The resulting molecular subclassification of glioblastoma, according to presence or absence of mutation in the isocitrate dehydrogenase 1 or 2 gene (*IDH* [OMIM 147700]), has prognostic significance.¹ Overall, approximately 91% of glioblastomas have *IDH*-wild-type mutations with median overall patient survival of 1.2 years, whereas the remaining 9% of tumors are *IDH* mutant, with a median overall patient survival of 3.6 years.² For both types of glioblastoma, the standard of care for patients with newly diagnosed disease is surgical resection followed by radiotherapy given in combination with the DNA-alkylating agent temozolomide.³ Maximum resection of contrast-enhanced (CE) tumor on T1-weighted magnetic resonance imaging has been consistently associated with longer survival.⁴⁻⁷ However, the association of maximal resection of the CE tumor with survival within glioblastoma subgroups and the potential importance of resection of non-contrast-enhanced (NCE) disease remain poorly understood.^{4,5,8-12} A clear understanding of the association of maximal extent of resection within molecular subgroups with survival is essential for counseling patients and medical decision-making.

We hypothesized that maximal extent of resection for CE and NCE tumor would be associated with improved patient survival regardless of *IDH* mutation status. The Stupp protocol³ with its accompanying improved survival became the accepted standard of care for glioblastoma in 2005. For this reason, we first focused our analysis on patients newly diagnosed with glioblastoma since 2005. In the first such study to our knowledge, we analyzed whether extent of resection of CE and NCE tumor was associated with overall survival among patients with known *IDH* mutation status. We then verified the findings in an independent patient cohort from 2 different institutions. Last, we examined overall survival in association with extent of resection among patients with known methylation status of the promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).¹³⁻¹⁶

Methods

In this retrospective, multicenter cohort study, overall survival risk models were first established in a development cohort and then tested in an external validation cohort, both of which are described below. Additional details on patient, tumor, imaging, and clinical data collection are given in the eMethods in the Supplement. The study was approved by the institutional review boards of the University of California, San Francisco (UCSF), Mayo Clinic, and the Cleveland Clinic. Written informed consent was obtained from all participants in all studies. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Development Cohort

Clinical and imaging data were retrievable for 761 of 1321 consecutive patients (57.6%) who were newly diagnosed with glioblastoma after 18 years of age and had an initial surgical procedure at UCSF from January 1, 1997, through

Key Points

Question Is maximal extent of resection of non-contrast-enhanced and contrast-enhanced tumor associated with improved survival within molecularly defined subgroups of newly diagnosed glioblastoma?

Findings In this cohort study of 761 patients with newly diagnosed glioblastoma, maximal resection of contrast-enhanced plus non-contrast-enhanced tumor was found to be associated with increased overall survival in younger patients, whereas maximal resection of contrast-enhanced tumor was associated with increased overall survival in older patients, regardless of molecular subgroup.

Meaning These findings indicate that maximal extent of resection of the contrast-enhanced tumor in all patients and the contrast-enhanced plus non-contrast-enhanced tumor in younger patients is associated with increased overall survival regardless of molecular subgroup and suggest a need to reconsider surgical strategies for these patients in the molecular era.

December 31, 2017 (Figure 1). The UCSF Cancer Registry was used to identify each patient's vital status, and data collection ended on December 10, 2018.


External Validation Cohort

The external validation cohort consisted of 206 patients from the Mayo Clinic and the Cleveland Clinic's Ohio Brain Tumor Study (OBTS) (eTable 1 in the Supplement). The Mayo Clinic provided clinical, surgical, and imaging data for 107 consecutive patients with newly diagnosed glioblastoma from January 1, 2004, through December 31, 2014. The OBTS is an ongoing prospective study and provided clinical, surgical, and imaging data for 99 consecutive patients with newly diagnosed glioblastoma from January 1, 2008, through December 31, 2011.

Summary of Statistical Methods

Data were analyzed from November 15, 2018, through March 15, 2019. Details of analytic methods are in the eMethods in the Supplement. To summarize, the characteristics considered for each patient are presented in the Table. We used the unpaired 2-tailed *t* and χ^2 tests to test for differences in these variables between cohorts. Overall survival was calculated from the date of first surgery until death or last follow-up. Cox proportional hazards regression models evaluated associations of variables with survival. The proportional hazards assumption was not met in all models, particularly for extent of resection; thus, we used recursive partitioning methods with all univariable significant variables except MGMT status (due to unstable imputed values [eMethods in the Supplement]). Recursive partitioning survival trees divided patients into different survival risk groups.^{17,18} Median overall survival, hazard ratios (HRs), and 95% CIs were computed for each risk group using the Kaplan-Meier method and Cox proportional hazards regression model with and without adjustment for MGMT status. Two-sided *P* < .05 indicated significance. All analyses were conducted using the statistical software R, version 3.5.1 (R Institute for Statistical Computing).

Figure 1. Data Flow Diagram for the UCSF Development Cohort



Results

Of the 761 patients with newly diagnosed glioblastoma in the UCSF development cohort, 468 (61.5%) were men and 293 (38.5%) were women; median age at diagnosis was 60 (interquartile range [IQR], 51.6-67.7) years (Table). Of the 514 patients with *IDH* measured, 478 (93.0%) had *IDH*-wild-type tumors; of the 205 with tumor MGMT methylation measured, 94 (45.9%) had MGMT methylated tumors. Similar to the findings of other studies, MGMT promoter methylation rates were lower (approximately 45%) in patients with *IDH*-wild-type tumors and higher (approximately 60%) in patients with *IDH*-mutant tumors.^{2,19} Of the 741 patients with treatment recorded, 619 (83.5%) received combined adjuvant temozolomide and radiotherapy, because 639 of the 761 patients in the cohort (84.0%) were diagnosed since 2005.³ The median percentage of CE tumor resected was 97% (IQR, 87%-100%), and the median percentage of NCE tumor resected was 54% (IQR, 39%-70%). Of the 514 patients with *IDH* measured, the percentage of CE tumor resected was the same in patients with *IDH*-wild-type glioblastoma as it was in patients with *IDH*-mutant glioblastoma (89.9% vs 89.5%; $P = .90$). As of December 10, 2018, median follow-up was 9.6 (95% CI, 7.7-13.4) years, and median overall survival was 14.2 (95% CI, 13.3-15.2) months. As of final data collection, 50 patients (6.6%) were still alive or lost to follow-up. In univariable models, age at diagnosis (HR, 1.42; 95% CI, 1.33-1.52; $P < .001$), Karnofsky Performance Score (KPS) (HR for 90-100, 0.60; 95% CI, 0.47-0.76; $P < .001$), *IDH* status (HR for *IDH*-mutant status, 0.26; 95% CI,

0.17-0.41; $P < .001$), MGMT status (HR for unmethylated status, 1.55; 95% CI, 1.14-2.10; $P = .005$), adjuvant radiotherapy (HR, 3.13; 95% CI, 2.30-4.25; $P < .001$), adjuvant temozolomide treatment (HR, 1.36; 95% CI, 1.01-1.82; $P = .04$), location of tumor (HR for cerebellum, 4.29; 95% CI, 1.06-17.37; $P = .04$), postoperative CE tumor volume (HR, 1.04; 95% CI, 1.03-1.05; $P < .001$), NCE tumor volume (HR, 1.01; 95% CI, 1.0-1.01; $P < .001$), and percentage extent of resection of the CE (HR, 0.99; 95% CI, 0.98-0.99; $P < .001$) and NCE (HR, 0.99; 95% CI, 0.99-0.99; $P < .001$) tumors were significantly associated with overall survival (eTable 2 in the Supplement). In eFigure 1 in the Supplement, the univariable association of percentage of enhancing tumor resected with the relative death rate is shown. Using a previously determined cutoff ranging from 75% to 80%,⁵ a reduction in the relative death rate was noted for resections of greater than 80%, whereas an increase in the relative death rate was noted for resections of less than 40%, with a plateau in effect from 40% to 80%.

Initially, we examined the association of extent of resection adjusted for other prognostic variables separated by *IDH* status in Cox proportional hazards regression models (eTable 3 in the Supplement). In patients with *IDH*-mutant tumors, the percentages of CE (HR, 0.95; 95% CI, 0.91-0.99; $P = .02$) and NCE (HR, 0.96; 95% CI, 0.93-0.99; $P = .02$) resected tumor were significantly associated with better survival, whereas other possible prognostic variables (ie, age, temozolomide treatment, and KPS) were not significantly associated with survival. The association of MGMT status with survival among these patients with *IDH*-mutant glioblastoma could not be assessed owing to the small number of tumors with MGMT

Table. Patient Characteristics^a

| Characteristic | UCSF Cohort (n = 761) | Post-2005/ <i>IDH</i> Known Subset (n = 434) |
|--|-----------------------|--|
| Sex | | |
| Male | 468/761 (61.5) | 271/434 (62.4) |
| Female | 293/761 (38.5) | 163/434 (37.6) |
| Age at diagnosis, y | | |
| Mean (SD) | 59.5 (12.0) | 59.6 (11.5) |
| Median (IQR) | 60.0 (51.6-67.7) | 60.5 (52.2-67.4) |
| Range | 19.0-89.0 | 21.3-89.0 |
| Diagnosis year | | |
| Before 2005 | 122/761 (16.0) | 0/434 |
| 2005 and after | 639/761 (84.0) | 434/434 (100) |
| KPS ^b | | |
| <60 | 35/451 (7.8) | 19/241 (7.9) |
| 60 | 24/451 (5.3) | 10/241 (4.1) |
| 70 | 50/451 (11.1) | 34/241 (14.1) |
| 80 | 149/451 (33.0) | 72/241 (29.9) |
| 90 | 173/451 (38.4) | 92/241 (38.2) |
| 100 | 20/451 (4.4) | 14/241 (5.8) |
| Median KPS (IQR) | 80 (80-90) | 80 (70-90) |
| Tumor location by lobe | | |
| Brainstem, insular, basal ganglia, or thalamus | 14/704 (2.0) | 11/414 (2.7) |
| Cerebellum | 2/704 (0.3) | 1/414 (0.2) |
| Frontal | 268/704 (38.1) | 153/414 (37.0) |
| Occipital | 46/704 (6.5) | 29/414 (7.0) |
| Parietal | 137/704 (19.5) | 74/414 (17.9) |
| Temporal | 237/704 (33.7) | 146/414 (35.3) |
| Tumor location by hemisphere | | |
| Bilateral | 8/705 (1.1) | 4/414 (1.0) |
| Left | 357/705 (50.6) | 205/414 (49.5) |
| Right | 340/705 (48.2) | 205/414 (49.5) |
| <i>IDH</i> status | | |
| Wild type | 478/514 (93.0) | 403/434 (92.9) |
| Mutant | 36/514 (7.0) | 31/434 (7.1) |
| MGMT status | | |
| Methylated | 94/205 (45.9) | 89/197 (45.2) |
| Unmethylated | 111/205 (54.1) | 108/197 (54.8) |
| Postoperative adjuvant therapy | | |
| Postoperative radiotherapy | 677/741 (91.4) | 399/424 (94.1) |
| Postoperative temozolomide | 628/741 (84.8) | 386/424 (91.0) |
| Both | 619/741 (83.5) | 380/424 (89.6) |
| Neither | 64/741 (8.6) | 20/424 (4.7) |
| Preoperative volume, mL | | |
| CE tumors | | |
| Mean (SD) | 32.6 (28.2) | 31.3 (27.9) |
| Median (IQR) | 24.8 (10.7-46.9) | 22.9 (11.0-44.3) |
| Range | 0.1-173.8 | 0.1-172.1 |
| NCE tumors | | |
| Mean (SD) | 85.3 (55.7) | 82.6 (54.7) |
| Median (IQR) | 75.0 (40.3-121.2) | 73.3 (37.7-121.1) |
| Range | 1.2-274.8 | 1.2-266.3 |

(continued)

Table. Patient Characteristics^a (continued)

| Characteristic | UCSF Cohort (n = 761) | Post-2005/ <i>IDH</i> Known Subset (n = 434) |
|----------------------------------|-----------------------|--|
| Postoperative volume, mL | | |
| CE tumors | | |
| Mean (SD) | 3.2 (6.9) | 3.1 (7.1) |
| Median (Q1-Q3) | 0.6 (0.0-3.1) | 0.5 (0.0-2.8) |
| Range | 0.0-57.6 | 0.0-57.6 |
| NCE tumors | | |
| Mean (SD) | 40.2 (33.4) | 36.7 (32.6) |
| Median (IQR) | 33.8 (13.5-56.8) | 29.8 (10.8-51.7) |
| Range | 0.0-200.3 | 0.0-200.3 |
| Extent of resection, % by volume | | |
| CE tumors | | |
| Mean (SD) | 89.6 (17.2) | 90.0 (16.9) |
| Median (Q1-Q3) | 97.3 (87.3-100) | 97.5 (88.4-100) |
| Range | 9.9-100.0 | 9.9-100.0 |
| NCE tumors | | |
| Mean (SD) | 53.7 (23.3) | 56.7 (23.3) |
| Median (Q1-Q3) | 54.0 (39.0-70.0) | 58.0 (43.0-73.0) |
| Range | 0.0-100 | 0.0-100 |

Abbreviations: CE, contrast enhanced; *IDH*, isocitrate dehydrogenase 1 or 2 gene; IQR, interquartile range; KPS, Karnofsky Performance Score; MGMT, promoter region of the DNA repair enzyme O6-methylguanine-DNA methyltransferase; NCE, non-contrast enhanced.

^a Unless otherwise indicated, data were expressed as number/total number (percentage) of patients. Percentages have been rounded and may not total 100.


^b Higher scores indicate a better ability to carry out daily activities.

methylation measured (7 of 36). In the *IDH*-wild-type subset, the percentage resected of CE (HR, 0.98; 95% CI, 0.97-0.99; $P < .001$) and NCE (HR, 0.99; 95% CI, 0.98-1.00; $P = .02$) tumors were each statistically significantly associated with better survival after adjusting for additional prognostic variables, including MGMT methylation status. The interaction of extent of resection (CE or NCE) and MGMT status was not statistically significant. Furthermore, because the proportional hazards assumptions were not met in either model for temozolomide treatment or percentage resected, we used recursive partitioning survival models for risk stratification as described in more detail below.

Post-2005 *IDH* Subset

Given the differences in chemotherapeutic administration before 2005, we performed a specific subgroup analysis of the 434 patients whose glioblastoma was diagnosed since 2005 and had known tumor *IDH* status (post-2005 *IDH* measured subset) (Figure 1B). Clinical and surgical characteristics were similar to those of the entire cohort (Table). Four distinct survival risk groups were identified via recursive partitioning (Figure 2 and Figure 3A). Group 1 patients (n = 38) were those who did not receive temozolomide and had the poorest overall survival (median, 3.6 [95% CI, 2.6-5.4] months). Group 2 patients (n = 122) had better overall survival than group 1 and included patients who had *IDH*-wild-type tumor, were treated

Figure 2. Recursive Partitioning Analysis (RPA) for Post-2005/*IDH*-Known Subset



Includes 434 patients. Four risk groups were determined by RPA based on adjuvant temozolomide treatment after surgery, isocitrate dehydrogenase gene 1 or 2 (*IDH*) status, age at diagnosis, and residual non-contrast-enhancing (NCE) tumor after surgery. Groups are denoted by numbers 1 through 4. Group 4 is the combination of 2 subgroups: temozolomide-treated patients with *IDH*-mutant tumors and temozolomide-treated patients aged 65 years or younger with *IDH*-wild-type tumors with no greater than 5.4 mL of NCE residual tumor.

with temozolomide, and were older than 65 years at diagnosis (median, 12.4 [95% CI, 11.4-14.0] months). Group 3 patients ($n = 212$) had better overall survival than patients in group 2 and included patients with *IDH*-wild-type tumors who received temozolomide, were younger than 65 years of age, and had more than 5.4 mL of residual NCE tumor after resection (median, 16.5 [95% CI, 14.7-18.3] months). Group 4 patients had the best overall survival and included 2 subgroups of temozolomide-treated patients: those with *IDH*-mutated tumors ($n = 28$) or those with *IDH*-wild-type tumors who were younger than 65 years with a median of 100% of CE tumor resected and a median of 90% resection of NCE tumor resulting in no more than 5.4 mL of residual NCE tumor ($n = 34$) (median, 37.3 [95% CI, 31.6-70.7] months). The younger patients with complete resection with an *IDH*-wild-type tumor (Group 4A, Figure 3B) had similar survival to patients with *IDH*-mutant tumors treated with temozolomide (Group 4B, Figure 3B) during the first 3 years of treatment. After 3 years, patients with *IDH*-wild-type tumors declined at a faster rate than did those with *IDH*-mutant tumors. Clinical characteristics and HRs (with and without adjustment for MGMT status and KPS) are shown in the caption for Figure 3A and eTables 4-6 in the Supplement. The risks remained significant after adjusting for MGMT status and KPS. The model is substantiated by the external validation cohort (Figure 3C), in which the HRs were significant and the median survivals were almost identical to the development set median survivals (caption of Figure 3C and eTable 8 in the Supplement). Clinical characteristics are shown in eTable 7 in the Supplement.

IDH-Wild-type Subset


Given the known superior prognosis of patients with *IDH*-mutant disease^{2,15,20} and the similarity observed in survival

with those with *IDH*-wild-type tumors who had extensive NCE tumor resection (Figure 2), we set out to determine the association of extent of resection with survival among patients in whom *IDH* was wild type regardless of diagnosis year ($n = 478$, Figure 1B). Four significant risk groups were identified (eFigure 3 in the Supplement). Group 1 patients ($n = 25$) were those who did not receive temozolomide and had more than 73.8 mL of NCE tumor preoperatively (median overall survival, 4.2 [95% CI, 3.3-4.9] months). Group 2 patients ($n = 200$) had better survival than group 1 patients and included those who did not receive temozolomide with less than or equal to 73.8 mL of NCE tumor preoperatively; those older than 65 years who did receive temozolomide; and those younger than 65 years who received temozolomide but had less than 77% of CE tumor resected (median overall survival, 11.6 [95% CI, 10.6-13.2] months). Group 3 patients ($n = 217$) had better survival than group 2 patients and were treated with temozolomide, were younger than 65 years of age, and had more than 77% of CE tumor resected with more than 5.4 mL residual NCE tumor (median overall survival, 17.9 [95% CI, 16.4-19.7] months). Group 4 patients ($n = 36$) had better survival than group 3 patients and were treated with temozolomide, were younger than 65 years, and had more than 77% of CE tumor resected and less than 5.4 mL of residual NCE tumor (median overall survival, 31.7 [95% CI, 22.2-56.2] months). Similar to the data above, the patients who had the best survival (group 4) were young with the most complete CE and NCE resections (ie, a median of 100% of the CE tumor resected and 92% of the NCE tumor resected) (eTable 9 in the Supplement). Clinical characteristics and HRs (with and without adjustment for MGMT and KPS) are shown in eFigure 3B and eTables 9 and 10 in the Supplement. The risk groups remain significant after adjusting for MGMT status and KPS. Validation included repeated imputation of *IDH* status for the 247 UCSF patients missing *IDH* status (eMethods 2 in the Supplement) in addition to the Mayo Clinic and OBTS cohorts (eFigure 3C in the Supplement).

Discussion

In 2019, more than 12 000 glioblastomas were diagnosed, accounting for more than 70% of all new gliomas.^{2,21} The WHO 2016 classification for brain and central nervous system tumors separates glioblastoma tumors into 2 groups, *IDH* mutant and wild type. To date, being younger, a higher KPS, treatment with temozolomide and radiotherapy, MGMT methylation, smaller CE tumor at presentation, and greater extent of resection of the CE tumor have consistently been associated with longer survival.^{2,9,12,15} The interplay between factors such as molecular classification and extent of resection has been a topic of intense interest. In addition, recent studies have attempted to determine whether there is benefit in resection of surrounding tumor that is NCE but hyperintense on T2-weighted or fluid-attenuated inversion recovery imaging.^{11,12,22} Herein we present the first study, to our knowledge, to examine the role of maximal resection of CE and NCE disease across glioblastoma subgroups for subsets of cases classified according to WHO 2016 classifications (*IDH* mutation

Figure 3. Kaplan-Meier Curves for Overall Survival for 4 Risk Groups



Groups are described in Figure 2. A, Includes patients in the post-2005 isocitrate dehydrogenase gene 1 or 2 status (*IDH*)-known (n = 434). For group 1, median overall survival was 3.6 (95% CI, 2.6-5.4) months (univariable hazard ratio [HR], 3.31 [95% CI, 2.31-4.74]; $P < .001$); group 2, 12.4 (95% CI, 11.4-14.0) months (univariable HR, 1.45 [95% CI, 1.15-1.83]; $P = .001$); group 3, 16.5 (95% CI, 14.7-18.3) months (univariable HR, 1 [reference]); and group 4, 37.3 (95% CI, 31.6-70.7) months (univariable HR, 0.36 [95% CI, 0.25-0.51]; $P < .001$). B, Includes groups 1 to 3 (gray) and the 2 subgroups in group 4. Group 4A represents the temozolomide-treated patients with *IDH*-wild-type tumors who were younger than 65 years and with no more than 5.4 mL of

non-contrast-enhancing residual tumor (median overall survival, 31.7 [95% CI, 22.2-43.9] months); group 4B, the temozolomide-treated patients with *IDH*-mutant tumors (median overall survival, 78.4 [95% CI, 35.1-not applicable] months). C, Includes Mayo Clinic (n = 107) and Ohio Brain Tumor Study (n = 99) patients with glioblastoma. Median overall survival for group 1 was 3.8 (95% CI, 2.4-4.6) months (univariable HR, 6.17 [95% CI, 4.08-9.33]; $P < .001$); group 2, 12.8 (95% CI, 10.9-14.6) months (univariable HR, 1.58 [95% CI, 1.11-2.25]; $P = .01$); group 3, 17.5 (95% CI, 15.3-22.5) months (univariable HR, 1 [reference]); and group 4, 32.4 (95% CI, 21.7-not applicable) months (univariable HR, 0.54 [95% CI, 0.31-0.94]; $P = .03$).


status) and by MGMT methylation status (eMethods in the Supplement), and to offer guidance for clinical decision-making by subgroup.

As a result of the seminal clinical trial published by Stupp et al³ in 2005, most patients with glioblastoma are treated with temozolomide and radiotherapy after surgery. For the purposes of a contemporary comparison, we restricted our UCSF cohort of 761 patients to those diagnosed since 2005 with *IDH* status measured (post-2005 *IDH* subset [n = 434]). The recursive partitioning analysis indicates that temozolomide-treated patients with *IDH*-mutant tumor and those patients younger than 65 years with

IDH-wild-type tumors have similar survival after maximal resection of NCE tumor and complete resection of CE tumor (Figure 2). In fact, these patients experience a similar survival to 3 years.

This study is the first, to our knowledge, in the molecular era to show that maximal resection of the NCE tumor in addition to that of the CE tumor outweighed the negative prognostic implication of *IDH*-wild-type status in younger patients. Prior published reports have suggested that patients with *IDH*-mutant gliomas are more likely to have complete tumor resection, potentially contributing to the survival benefit seen from aggressive resection.²³ However, in the subset

Figure 4. Proposed Surgical Strategy for Newly Diagnosed Glioblastoma



Strategy consists of maximal resection of the contrast-enhanced (CE) tumors for all patients with the additional maximum resection of the non-contrast-enhanced (NCE) tumors for patients younger than 65 years, when safely feasible.

of patients in our large cohort whose tumors were tested for *IDH*, extent of resection was the same in patients with *IDH*-wild-type glioblastoma as it was in patients with *IDH*-mutant glioblastoma (89.9% vs 89.5%; $P = .90$ [$n = 514$]). It therefore appears unlikely that extent of resection of CE disease is simply a surrogate for *IDH* status, in contrast with previously published results.²³

Most newly diagnosed glioblastomas are *IDH* wild type. We therefore performed a specific analysis of *IDH*-wild-type glioblastoma, noting important differences after the patients with favorable *IDH*-mutant tumors were removed. Again, the recursive partitioning analysis based on this subset indicates that for temozolomide-treated patients younger than 65 years, maximal resection of CE and NCE tumor is associated with improved overall survival (median, 31.7 vs 11.6 months) (eFigure 3 and eTables 10 and 11 in the [Supplement](#)). This finding does not support a previous report²³ suggesting that only patients with *IDH*-mutant tumors benefit from maximal resection of the CE and NCE disease, whereas those with *IDH*-wild-type tumors benefit solely from resection of the enhancing disease. The previous study focused on resection and *IDH* status as main effects in a smaller cohort of patients; thus, the interaction among *IDH* status, age, and resection of CE and NCE disease was likely missed. For those older than 65 years in the present study, resection of the CE tumor was associated with improved survival (with adjustment for MGMT status), whereas resection of NCE tumor was not (eTable 11 in the [Supplement](#)).

Given that MGMT methylation improves prediction and prognosis, we looked at the association of MGMT status with the risk groups (eTables 6 and 10 in the [Supplement](#)). The association of the risk groups remained significant when adjusted for MGMT status, signifying the risk groups as independently associated with survival; and the interactions were insignificant, signifying that the association of the risk groups does not differ by MGMT status (see discussion in eTable 6D in the [Supplement](#)). We also performed an analysis on those patients with MGMT methylation measured separated by methylation status ($n = 205$) (Figure 1B and eMethods in the [Supplement](#)). In the 2 subsets, the patients treated with temozolomide (for the MGMT-methylated tumors) or younger than 65 years (for the MGMT-unmethylated tumors) who had maximum resection of the CE (median, 100%) and NCE (median, 63%-64%) tumor had the best and most similar survival (eFigures 4-7 and eTables 12-15 in the [Supplement](#)).

In summary, we found that reduction of CE tumor was significant regardless of *IDH* status and MGMT methylation status. Reduction of NCE tumor was significant in younger (<65 years) patients with *IDH*-wild-type tumors, regardless of MGMT status, and in all patients with *IDH*-mutant tumors. Thus, our proposed surgical strategy for newly diagnosed glioblastoma is to perform maximal resection of the CE tumor for all patients with the additional maximum resection of the NCE tumor in patients younger than 65 years, when safely feasible (Figure 4). Given the younger ages of patients with *IDH*-mutant tumors (median age, 38 years²), this guideline incorporates them in the younger group.

Limitations

This study has several limitations. This retrospective cohort involves patients from 3 large tertiary referral centers rather than a randomized clinical trial. As a surgical series, the distribution of volume resected is skewed toward surgically resectable glioblastoma, not tumors for which a neurosurgeon might recommend biopsy alone. Although we believe greater extent of resection, particularly of NCE disease, does not result in greater neurological compromise, we cannot comment on this topic in our data; in support, however, a large study ($n = 643$) comparing complete CE tumor resection with at least 53% vs less than 53% NCE resection found a significantly higher overall complication rate in the patients with less than 53% resection and a comparable rate of neurological complications between the 2 groups.¹² In most cases, decisions about extent of resection are made without prior knowledge of molecular subclassification. Treating newly diagnosed presumed glioblastomas with biopsy before definitive resection is costly and would delay postresection chemoradiotherapy. Radiomic approaches and serum biomarkers have demonstrated the ability to diagnose glioblastoma based on imaging²⁴ or serum samples only,²⁵ but none of these innovations are currently available for clinical use. In light of these data, clinicians can make inferences about molecular subclassification based on previously published large-scale genomic analyses.

Conclusions

This study is the first, to our knowledge, to combine resection of CE and NCE tumors in conjunction with molecular and clinical information with validation in an external test set and paves the way for rethinking surgical strategies for individual patients with newly diagnosed glioblastoma. This study supports maximal extent of resection for the CE tumor, and in younger patients, the additional maximal resection of the NCE tumor, regardless of *IDH* and MGMT status. To maximize CE and NCE resection, advanced intraoperative imaging methods and fluorescence-based tumor biomarkers can be used, whereas stimulation mapping²⁶ will help to decrease perioperative morbidity.

ARTICLE INFORMATION

Accepted for Publication: November 6, 2019.

Published Online: February 6, 2020.
doi:10.1001/jamaoncol.2019.6143

Author Affiliations: Department of Neurological Surgery, University of California, San Francisco (Molinaro, Hervey-Jumper, Morshed, Young, Chunduru, Zhang, Phillips, Shai, Chandra, Flanigan, Rice, Wrensch, Wiencke, Oberheim Bush, Taylor, Butowski, Prados, Clarke, S. Chang, E. Chang, Aghi, Theodosopoulos, McDermott, Berger); Department of Neurological Surgery, Oregon Health Sciences University, Portland (Han); Department of Pathology, University of California, San Francisco (Phillips); Department of Radiology and Biomedical Imaging, University of California, San Francisco (Lafontaine, Crane, Villanueva-Meyer); Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia (Jahangiri); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (Cioffi, Anderson, Badve, Barnholtz-Sloan, Sloan); Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas (Ostrom); Department of Radiology, University Hospitals of Cleveland, Cleveland, Ohio (Anderson, Badve); Research Division, University Hospitals of Cleveland, Cleveland, Ohio (Barnholtz-Sloan); Seidman Cancer Center, University Hospitals of Cleveland, Cleveland, Ohio (Sloan); Mayo Clinic, Rochester, Minnesota (Erickson, Decker, Kosel, LaChance, Eckel-Passow, Jenkins); Department of Neurology, University of California, San Francisco (Oberheim Bush, Taylor, Clarke).

Author Contributions: Dr Molinaro had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Molinaro, Hervey-Jumper, Han, Jahangiri, Erickson, Villanueva-Meyer, Wrensch, Butowski, S. Chang, McDermott, Berger.

Acquisition, analysis, or interpretation of data:

Molinaro, Hervey-Jumper, Morshed, Young, Han, Chunduru, Zhang, Phillips, Shai, Lafontaine, Crane, Chandra, Flanigan, Jahangiri, Cioffi, Ostrom, Anderson, Badve, Barnholtz-Sloan, Sloan, Erickson, Decker, Kosel, Lachance, Eckel-Passow, Jenkins, Villanueva-Meyer, Rice, Wrensch, Wiencke, Oberheim Bush, Taylor, Prados, Clarke, S. Chang, E. Chang, Aghi, Theodosopoulos.

Drafting of the manuscript: Molinaro, Hervey-Jumper, Morshed, Chunduru, Zhang, Chandra, Anderson, Jenkins, Taylor, Butowski.
Critical revision of the manuscript for important intellectual content: Molinaro, Hervey-Jumper, Morshed, Young, Han, Phillips, Shai, Lafontaine, Crane, Chandra, Flanigan, Jahangiri, Cioffi, Ostrom, Badve, Barnholtz-Sloan, Sloan, Erickson, Decker, Kosel, Lachance, Eckel-Passow, Jenkins, Villanueva-Meyer, Rice, Wrensch, Wiencke, Oberheim Bush, Prados, Clarke, S. Chang, E. Chang, Aghi, Theodosopoulos, McDermott, Berger.
Statistical analysis: Molinaro, Hervey-Jumper, Chunduru, Zhang, Cioffi, Barnholtz-Sloan, Decker, Kosel, Eckel-Passow.

Obtained funding: Molinaro, Hervey-Jumper, Jenkins, Wrensch, Wiencke.

Administrative, technical, or material support: Molinaro, Hervey-Jumper, Morshed, Han, Phillips,

Shai, Lafontaine, Crane, Flanigan, Jahangiri, Cioffi, Anderson, Badve, Sloan, Erickson, Jenkins, Villanueva-Meyer, Rice, Wiencke, Taylor, Butowski, Prados, Clarke, E. Chang, Aghi, Theodosopoulos.
Supervision: Molinaro, Hervey-Jumper, Han, Flanigan, Sloan, Erickson, Jenkins, Villanueva-Meyer, Prados, S. Chang, Aghi, Theodosopoulos, McDermott.

Conflict of Interest Disclosures: Dr Phillips reported receiving grants from the National Institutes of Health/National Cancer Institute (NIH/NCI) during the conduct of the study. Dr Badve reported receiving grants and intellectual property in the form of patents and royalties from the Clinical and Translational Science Center and Case Cancer Center outside the submitted work. Dr Wrensch reported receiving grants from NCI and funding from private donors (known as the Loglio Collective) to the UCSF Neurological Surgery Department during the conduct of the study. Dr Taylor reported receiving grants from Agios Pharmaceuticals, Inc, Bristol-Myers Squibb, and AbbVie, Inc, outside the submitted work. Dr Prados reported receiving grants from Brain Tumor SPORE during the conduct of the study. Dr Clarke reported receiving grants and personal fees from Agios Pharmaceuticals, Inc, Genentech/Roche, Merck & Co, and Novartis International AG outside the submitted work. No other disclosures were reported.

Funding/Support: This study was supported by grants R01CA52689, P50CA097257, R01CA126831, and K08 12649025 from the NIH, the Loglio Collective, the Stanley D. Lewis and Virginia S. Lewis Endowed Chair in Brain Tumor Research, the Robert Magnin Newman Endowed Chair in Neuro-oncology, and donations from families and friends of John Berardi, Helen Glaser, Elvera Olsen, Raymond E. Cooper, and William Martinussen at the University of California, San Francisco (UCSF). The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; cooperative agreement 5NU58DPO06344 by the Centers for Disease Control and Prevention's National Program of Cancer Registries; contract HHSN2612018000321 from the NCI's Surveillance, Epidemiology and End Results Program (UCSF), contract HHSN2612018000151 (University of Southern California), and contract HHSN2612018000091 (Public Health Institute, Cancer Registry of Greater California).

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The ideas and opinions expressed herein are those of the authors and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the CDC or their contractors and subcontractors.

Additional Contributions: Sarah Nelson, PhD, UCSF, made significant contributions to this study. Nicole Ebrahimi, BS, RN, Yi Lin, MD, and Gayathri Warrior, MS, UCSF, contributed to data collection. Karen Devine, RN, Julia Schroer, MS, Haley

Gittleman, PhD, and Kristin Waite, PhD, OBTS, contributed to data collection and organization. None of these individuals were compensated outside their normal salaries. We thank the study participants, clinicians, and research staff at the participating medical centers, the UCSF Cancer Registry, and the UCSF Neurosurgery Tissue Bank.

REFERENCES

- Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol*. 2016;131(6):803-820. doi:10.1007/s00401-016-1545-1
- Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. Genetic and molecular epidemiology of adult diffuse glioma. *Nat Rev Neurol*. 2019;15(7):405-417. doi:10.1038/s41582-019-0220-2
- Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. *Curr Neurol Neurosci Rep*. 2005;5(3):198-206. doi:10.1007/s11910-005-0047-7
- McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. *J Neurosurg*. 2009;110(1):156-162. doi:10.3171/2008.4.17536
- Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. *J Neurosurg*. 2011;115(1):3-8. doi:10.3171/2011.2.JNS10998
- Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol*. 2006;7(5):392-401. doi:10.1016/S1470-2045(06)70665-9
- Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. *Acta Neurochir (Wien)*. 2011;153(6):1211-1218. doi:10.1007/s00701-011-1001-x
- Stummer W, Reulen HJ, Meinel T, et al; ALA-Glioma Study Group. Extent of resection and survival in glioblastoma multiforme: identification of an adjustment for bias. *Neurosurgery*. 2008;62(3):564-576. doi:10.1227/01.neu.0000317304.31579.17
- Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. *J Clin Oncol*. 2014;32(8):774-782. doi:10.1200/JCO.2013.51.8886
- Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *J Neurosurg*. 2001;95(2):190-198. doi:10.3171/jns.2001.95.2.0190
- Pessina F, Navarra P, Cozzi L, et al. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? a single institution retrospective experience. *J Neurooncol*. 2017;135(1):129-139. doi:10.1007/s11060-017-2559-9

12. Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? *J Neurosurg*. 2016;124(4):977-988. doi:10.3171/2015.5.JNS142087
13. Wick W, Weller M, van den Bent M, et al. MGMT testing—the challenges for biomarker-based glioma treatment. *Nat Rev Neurol*. 2014;10(7):372-385. doi:10.1038/nrneuro.2014.100
14. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med*. 2005;352(10):997-1003. doi:10.1056/NEJMoa043331
15. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. *J Clin Oncol*. 2009;27(34):5743-5750. doi:10.1200/JCO.2009.23.0805
16. Malmström A, Grønberg BH, Marosi C, et al; Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. *Lancet Oncol*. 2012;13(9):916-926. doi:10.1016/S1470-2045(12)70265-6
17. Molinaro AM, Lostritto K, van der Laan M. partDSA: deletion/substitution/addition algorithm for partitioning the covariate space in prediction. *Bioinformatics*. 2010;26(10):1357-1363. doi:10.1093/bioinformatics/btq142
18. Lostritto K, Strawderman RL, Molinaro AM. A partitioning deletion/substitution/addition algorithm for creating survival risk groups. *Biometrics*. 2012;68(4):1146-1156. doi:10.1111/j.1541-0420.2012.01756.x
19. Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG Oncology/RTOG 0424 trial. *JAMA Oncol*. 2018;4(10):1405-1409. doi:10.1001/jamaoncol.2018.1977
20. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. *N Engl J Med*. 2015;372(26):2499-2508. doi:10.1056/NEJMoa1407279
21. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. *Neuro Oncol*. 2018;20(suppl 4):iv1-iv86. doi:10.1093/neuonc/now131
22. Lasocki A, Gaillard F. Non-contrast-enhancing tumor: a new frontier in glioblastoma research. *AJNR Am J Neuroradiol*. 2019;40(5):758-765. doi:10.3174/ajnr.A6025
23. Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. *Neuro Oncol*. 2014;16(1):81-91. doi:10.1093/neuonc/not159
24. Akbari H, Macyszyn L, Da X, et al. Imaging surrogates of infiltration obtained via multiparametric imaging pattern analysis predict subsequent location of recurrence of glioblastoma. *Neurosurgery*. 2016;78(4):572-580. doi:10.1227/NEU.0000000000001202
25. Soler DC, Young AB, Cooper KD, et al. The ratio of HLA-DR and VNN2* expression on CD14* myeloid derived suppressor cells can distinguish glioblastoma from radiation necrosis patients. *J Neurooncol*. 2017;134(1):189-196. doi:10.1007/s11060-017-2508-7
26. Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. *N Engl J Med*. 2008;358(1):18-27. doi:10.1056/NEJMoa067819